Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 277

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 277
---
 FINANCIAL STATEMENTS

U.S. dollars in thousands, exceptshare and per share data

| NOTE 3:- | OTHER CURRENT ASSETS |

|                                           |     |   | December 31, 2023 |     |   | December 31, 2022 |
|:------------------------------------------|:----|:--|------------------:|:----|:--|------------------:|
| Receivables from governmental authorities |     | $ |                 8 |     | $ |                26 |
| Prepaid expenses                          |     |   |                 7 |     |   |               451 |
|                                           |     | $ |                15 |     | $ |               477 |

| NOTE 4:- | OTHER ACCOUNTS PAYABLE |

|                               |     |   | December 31, 
         2023 |     |   | December 31, 
         2022 |
|:------------------------------|:----|:--|-------------:|:----|:--|-------------:|
| Grant liability               |     | $ |        2,054 |     | $ |        1,981 |
| Accrued expenses              |     |   |          518 |     |   |          418 |
| Accrued employee compensation |     |   |            3 |     |   |            2 |
| Other payables                |     |   |            1 |     |   |            2 |
| Total                         |     | $ |        2,576 |     | $ |        2,403 |

| NOTE 5:- | SHORT-TERM LOAN |

On August 15, 2023, the Company obtained
a loan at an aggregate amount of $325 from current shareholders and officers of the Company and several new investors. According to the
loan agreement, the loan will be repaid within 30 days at the earlier of:

| 1. | Receipt of a grant of 300,000          
 Euro from the Horizon 2020 Program, or |

| 2. | Consummation of the merger 
 with OceanTech.            |

The Company classified the loan as
a current liability and estimated repayment of the loan until March 31, 2024. In addition, as part of the loan agreement, the Company
issued to each lender warrants exercisable into ordinary shares of the Company (refer to Note 11).

The proceeds from the loan agreements
were allocated at the